Market Challenges And Opportunities

High prevalence of Polycystic Ovary Syndrome (PCOS) drives the in vitro fertilization devices market in near future

According to the CDC, in 2016, PCOS was found to be the major cause of female infertility, which has affected around 5 million women during the reproductive age, in the U.S. Women with PCOS have low levels of follicle stimulating hormone (FSH) and high levels of androgen (male hormone), which significantly affects ovulation and creates difficulties to conceive. Moreover, half of women suffering from PCOS, develop type 2 diabetes, which further leads to complications associated with fertility. Consequently, increasing incidence of PCOS for women, is driving demand for in-vitro fertilization devices, which in turn, is expected to fuel growth of the market in the near future.

High costs associated with in-vitro fertilization procedure is expected to hamper growth of the in vitro fertilization devices market

The American Society for Reproductive Medicine (ASRM), reported that the average cost of an IVF cycle in the U.S. is around US$ 12,400, which includes fertility medications, preliminary test, ultrasound monitoring, and blood tests. However, number of IVF cycles required depends upon the patient’s age and quality of the embryo and semen. Furthermore, depending on patient’s circumstance, the demand for ART treatment such as Intra Cytoplasmic Sperm Injection (ICSI) is expected to increase, in turn, increasing the costs associated with in-vitro fertilization by US$ 1,000 to US$ 3,000. Thus, the overall treatment methods make in-vitro fertilization expensive, in turn, restraining growth of the in vitro fertilization devices market.